诺和诺德公布了一项研究，结果显示将Ozempic剂量增加到2毫克可降低重大心血管事件的风险。
周二，诺和诺德表示，一项真实世界研究发现，服用其糖尿病药物Ozempic剂量增加的2型糖尿病患者，其重大心血管事件的发生率低于那些转用礼来公司药物的患者。
Novo reveals a study of patients who increased their Ozempic dose to 2mg to lower the major risk of cardiovascular incidents On Tuesday, Novo Nordisk said that a real-world study found that adults with type 2 diabetes who took an increased dose of its diabetes drug, Ozempic, had fewer major cardiovascular events compared to those who switched to Eli Lilly’s drug.
公司进一步指出，将Ozempic剂量从1毫克增加到2毫克的患者，其发生严重有害心血管事件的风险降低了6%，这一结果具有统计学意义。
The company further said that patients who increased their dose to Ozempic to 2 milligrams from 1 mg saw a statistically reliable 6% lower risk of significant harmful cardiovascular events compared to those who use Mounjaro doses of up to 15mg.
关键研究结果在意大利举行的欧洲糖尿病研究协会年会上公布，分析了636,525名患者的数据。
其中67.2%的患者在首次开药后的365天内仍继续使用1毫克剂量的Ozempic；29.2%的患者将剂量增加到2毫克或转用了Mounjaro。
The key findings were presented at the European Association for the Study of Diabetes annual meeting in Italy with analysis of 636,525 adults, 67.2% remained on Ozempic 1mg within 365 days of their first prescription. Notably, an 29.2% also increased to Ozempic 2mg or switched to Mounjaro.
720天的随访显示，57.4%的患者仍使用1毫克剂量的Ozempic，36.9%的患者将剂量增加到2毫克。
The reports further showed that at the 720-day follow-up 57.4% had stuck with Ozempic 1mg with 36.9% rising to 2mg.
这些发现扩展了之前对HbA1c（血糖控制指标）和体重减轻效果的评估。
The findings extend a prior evaluation of these data which examined HbA1c, a measure of glycemic control and weight loss.
诺和诺德的医学总监Michael Radin表示：‘这些真实世界的研究结果有助于了解强化治疗策略如何影响心血管结局，这是患者健康的重要因素。’
In this connection, Michael Radin, medical director at Novo said: “These real-world findings can help provide insights into how intensification strategies may affect cardiovascular outcomes as an important factor in patient car.”
诺和诺德与礼来在美国肥胖药物市场上展开激烈竞争，分析师预计该市场的规模到2030年将达到1000亿至1500亿美元。’
Novo and Lilly are engaged in a power struggle in the US obesity drug market which analysts project to be worth between $100 billion and $150 billion by 2030.